TY - JOUR
T1 - Gleason grade group concordance between preoperative targeted biopsy and radical prostatectomy histopathologic analysis
T2 - A comparison between in-bore mri-guided and mri–transrectal us fusion prostate biopsies
AU - Costa, Daniel N.
AU - Cai, Qi
AU - Xi, Yin
AU - Recchimuzzi, Debora Z.
AU - Subramanian, Naveen
AU - Bagrodia, Aditya
AU - Rofsky, Neil M
AU - Roehrborn, Claus G.
AU - Hornberger, Brad J
AU - Shah, Rajal B.
AU - Goldberg, Kenneth
AU - Diaz De Leon III, Alberto
AU - Pedrosa, Ivan
N1 - Publisher Copyright:
© RSNA, 2021.
PY - 2021/3
Y1 - 2021/3
N2 - Purpose: To determine and compare rates of grade group (GG) discrepancies between different targeted biopsy techniques (in-bore vs fusion) after propensity score weighting using whole-mount radical prostatectomy (RP) histopathologic analysis as the reference standard. Materials and Methods: This retrospective study evaluated men who underwent targeted (fusion or in-bore) biopsy between April 2017 and January 2019 followed by prostatectomy. The primary endpoint of the study was a change in GG from biopsy to RP at a patient level. For downgrade and upgrade analysis, men with biopsy GG1 (downgrade not possible) and GG5 (upgrade not possible) were ex-cluded, respectively. GG upgrade, downgrade, and concordance rates of each targeting approach were compared using propensity score weighting and logistic regression with inverse probability of treatment weighting. Significance level was set at.05. Index lesion GG on RP specimen served as the reference standard. Results: A total of 191 men (90 in the in-bore [mean age, 63 years ± 7 (standard deviation)] and 101 in the fusion biopsy group [mean age, 65 years ± 7]) were eligible and included. Fewer GG upgrades were noted in the in-bore biopsy group (14%; 12 of 85) compared with the fusion plus systematic biopsy group (30%; 28 of 93) (P =.012). The incidence of GG downgrade in the in-bore group (25%; 21 of 84) was higher than in the fusion group (17%; 16 of 93); however, the difference was not statistically significant (P =.2). Of the 77 men misclassified by both biopsy techniques, the majority (56%, n = 43) had a change in GG of 2 to 3 or 3 to 2. Conclusion: Superior sampling accuracy with MRI-guided in-bore biopsies offers a lower incidence of GG upgrades compared with MRI–transrectal US fusion biopsies upon RP.
AB - Purpose: To determine and compare rates of grade group (GG) discrepancies between different targeted biopsy techniques (in-bore vs fusion) after propensity score weighting using whole-mount radical prostatectomy (RP) histopathologic analysis as the reference standard. Materials and Methods: This retrospective study evaluated men who underwent targeted (fusion or in-bore) biopsy between April 2017 and January 2019 followed by prostatectomy. The primary endpoint of the study was a change in GG from biopsy to RP at a patient level. For downgrade and upgrade analysis, men with biopsy GG1 (downgrade not possible) and GG5 (upgrade not possible) were ex-cluded, respectively. GG upgrade, downgrade, and concordance rates of each targeting approach were compared using propensity score weighting and logistic regression with inverse probability of treatment weighting. Significance level was set at.05. Index lesion GG on RP specimen served as the reference standard. Results: A total of 191 men (90 in the in-bore [mean age, 63 years ± 7 (standard deviation)] and 101 in the fusion biopsy group [mean age, 65 years ± 7]) were eligible and included. Fewer GG upgrades were noted in the in-bore biopsy group (14%; 12 of 85) compared with the fusion plus systematic biopsy group (30%; 28 of 93) (P =.012). The incidence of GG downgrade in the in-bore group (25%; 21 of 84) was higher than in the fusion group (17%; 16 of 93); however, the difference was not statistically significant (P =.2). Of the 77 men misclassified by both biopsy techniques, the majority (56%, n = 43) had a change in GG of 2 to 3 or 3 to 2. Conclusion: Superior sampling accuracy with MRI-guided in-bore biopsies offers a lower incidence of GG upgrades compared with MRI–transrectal US fusion biopsies upon RP.
UR - http://www.scopus.com/inward/record.url?scp=85107595671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107595671&partnerID=8YFLogxK
U2 - 10.1148/rycan.2021200123
DO - 10.1148/rycan.2021200123
M3 - Article
C2 - 33817652
AN - SCOPUS:85107595671
SN - 2638-616X
VL - 3
JO - Radiology: Imaging Cancer
JF - Radiology: Imaging Cancer
IS - 2
M1 - e200123
ER -